编号：2022-01-12 股票代码：002734 股票简称：利民股份 利民控股集团股份有限公司投资者关系活动记录表 | --- | --- | |---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-11-17 股票代码：002734 股票简称：利民股份 利民控股集团股份有限公司投资者关系活动记录表 | --- | --- | |----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's revenue for Q3 2022 was ¥1,233,401,008.19, representing a 6.25% increase year-over-year[5] - Net profit attributable to shareholders for Q3 2022 was ¥27,682,864.86, a 22.00% increase compared to the same period last year[5] - The basic earnings per share for Q3 2022 was ¥0.07, reflecting a 16.67% increase year-over-year[5] - In Q3 2022, the company achieved operating revenue of CNY 1.233 billion, a year-on-year increase of 6.25%[13] - The net profit attributable to shareholders in Q3 2022 was CNY 27.68 million, representing a 22% increase year-on-year[14] - However, for the first nine months, the net profit attributable to shareholders decreased by 33.69% to CNY 179 million, primarily due to logistics disruptions and rising raw material costs[14] - Total operating revenue for the third quarter of 2022 reached CNY 4,042,093,577.37, an increase of 9.2% compared to CNY 3,701,281,699.85 in the same period last year[20] - Net profit for the third quarter was CNY 184,918,304.21, a decrease of 36.8% from CNY 292,207,347.02 in the previous year[21] Assets and Liabilities - The total assets at the end of the reporting period reached ¥7,876,262,688.84, marking a 14.43% increase from the end of the previous year[5] - The company's total assets increased to CNY 7,876,262,688.84, compared to CNY 6,883,292,562.29 at the end of the previous year, reflecting a growth of 14.4%[19] - Current liabilities rose to CNY 3,694,169,280.94, an increase of 29.9% from CNY 2,846,889,618.25 year-on-year[19] - Long-term borrowings increased to CNY 429,960,000.00, compared to CNY 225,000,000.00 in the previous year, marking a growth of 91.1%[19] - The total liabilities of the company reached CNY 5,087,843,910.87, an increase of 27.1% from CNY 4,004,332,993.18 in the previous year[19] - The equity attributable to shareholders of the parent company was CNY 2,742,273,435.39, up from CNY 2,701,468,431.73 year-on-year, reflecting a growth of 1.5%[19] Cash Flow - The cash flow from operating activities showed a significant increase of 255.72%, totaling ¥381,653,409.53[5] - The net cash flow from operating activities for the first nine months was CNY 382 million, an increase of CNY 627 million year-on-year[14] - Net cash flow from operating activities was CNY 381,653,409.53, compared to a negative cash flow of CNY -245,085,620.65 in the previous period[25] - Cash inflow from operating activities totaled CNY 3,182,234,629.72, up from CNY 2,528,757,883.50 in the previous period[25] - Cash outflow from investing activities was CNY 1,566,044,922.18, compared to CNY 942,047,039.40 in the previous period[25] - Net cash flow from financing activities was CNY 561,099,301.25, down from CNY 995,865,505.58 in the previous period[25] - The ending balance of cash and cash equivalents was CNY 597,984,823.15, down from CNY 767,349,882.32 in the previous period[25] - The company received CNY 432,650,000.00 from investment recoveries, significantly higher than CNY 168,000,000.00 in the previous period[25] - The company paid CNY 465,034,117.44 in employee compensation, an increase from CNY 425,801,470.52 in the previous period[25] - The company reported a total cash inflow from financing activities of CNY 1,789,787,386.30, compared to CNY 1,898,330,000.00 in the previous period[25] Investments and Projects - The company's investment income decreased by 62.30% due to a decline in profits from associated companies[9] - The accounts receivable increased by 140.78%, primarily due to delayed payments[9] - The company reported a 36.79% increase in notes payable, attributed to an increase in bank acceptance bills[9] - The company organized 2,264 promotional activities and efficacy trials to enhance brand cultivation and promotion of core products[14] - The construction of the 5,000-ton glyphosate project was completed by September 30, 2022[15] - The company is advancing the new energy lithium salt project and the L-glyphosate project, with industrialization processes being accelerated[15] - The company plans to leverage rising prices of main products and decreasing raw material costs to enhance overall profitability in Q4 2022[15] - The company is focusing on international market expansion and product registration to drive sales growth[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,849[11] - The largest shareholder, Li Ming, holds 19.79% of the shares, with 28,580,000 shares pledged[11] Research and Development - Research and development expenses for the quarter were CNY 128,312,896.58, slightly down from CNY 133,976,717.04 in the same period last year[21] Financial Expenses - The company reported a decrease in financial expenses to CNY 11,697,349.91 from CNY 49,787,006.73 year-on-year[21] Comprehensive Income - The total comprehensive income for the period was CNY 187,268,818.12, a decrease from CNY 292,041,897.05 in the previous period[22] - Basic earnings per share decreased to CNY 0.48 from CNY 0.72 year-over-year[22]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥2,808,692,569.18, representing a 10.56% increase compared to ¥2,540,464,320.04 in the same period last year[22]. - The net profit attributable to shareholders decreased by 38.80% to ¥151,327,409.03 from ¥247,259,941.59 year-on-year[22]. - Basic earnings per share fell by 37.88% to ¥0.41, down from ¥0.66 in the same period last year[22]. - The company reported a decrease of 40.26% in net profit after deducting non-recurring gains and losses, amounting to ¥143,201,850.06 compared to ¥239,722,888.27 last year[22]. - The weighted average return on net assets decreased to 5.08% from 9.91% in the previous year, reflecting a decline of 4.83%[22]. - The company's net profit after deducting non-recurring gains and losses for the first half of 2022 was 15,108.3 million yuan, a decrease of 42.09% compared to the same period last year[181]. - The net profit for the first half of 2022 was CNY 159,208,488.86, a decrease of 40.7% from CNY 268,434,861.18 in the first half of 2021[194]. - The total comprehensive income for the first half of 2022 was CNY 160,135,316.13, compared to CNY 268,164,297.59 in the same period of 2021[195]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching ¥252,291,219.60, compared to a negative cash flow of ¥282,707,788.97 in the previous year, marking a 189.24% increase[22]. - Cash and cash equivalents at the end of the reporting period amounted to 1,272,853,600, representing 16.54% of total assets, an increase of 2.45% compared to the previous year[54]. - The company's cash interest coverage ratio improved to 6.55, a significant increase of 179.88% compared to -8.2 in the previous year[181]. - Operating cash flow for the first half of 2022 was CNY 252,291,219.60, compared to a negative cash flow of CNY -282,707,788.97 in the first half of 2021[200]. Assets and Liabilities - Total assets increased by 11.83% to ¥7,697,795,509.02 from ¥6,883,292,562.29 at the end of the previous year[22]. - The company's total liabilities increased to CNY 1,530,770,268.11, compared to CNY 1,202,865,554.25 in the previous year, reflecting a growth of 27.3%[194]. - The company's asset-liability ratio increased to 64.15% as of June 30, 2022, up from 58.17% at the end of 2021, representing a 5.98% increase[179]. - Total liabilities amounted to CNY 4.94 billion, up from CNY 4.00 billion, which is an increase of about 23.5%[188]. Investments and R&D - The company's R&D investment decreased by 8.16% to ¥82,025,940.12 from ¥89,309,896.54 year-on-year[47]. - The company has established five R&D platforms and is actively exploring new technology applications in "new energy materials" and "synthetic biology," including a joint venture for lithium battery chemical research and production[40]. - The company is focusing on technological upgrades and new product development to maintain competitive advantages and create new profit points[75]. Market Presence and Strategy - The company is recognized as a leading domestic pesticide manufacturer, with significant production capacity in key products such as mancozeb and flumioxazin[34]. - The company’s products have received various international certifications, including FDA and GMP, enhancing its competitive edge[35]. - The company’s sales market covers over 130 countries and regions, indicating a strong international presence[34]. - The company is focusing on green and safe agricultural practices, aligning with national policies for sustainable development in the pesticide industry[32]. Environmental Compliance - The company is committed to improving its environmental governance and carbon reduction capabilities in response to increasing ESG standards[75]. - The company has implemented continuous monitoring systems to ensure ongoing compliance with environmental standards[86]. - The company has established 3 comprehensive wastewater treatment facilities with a daily processing capacity of 8,300 tons, ensuring wastewater meets discharge standards before entering the local sewage treatment plant[89]. Safety and Risk Management - The company has a dedicated safety management team with 27 safety management personnel and 19 registered safety engineers to oversee production safety[105]. - The company emphasizes environmental protection and adheres to national standards, achieving no major safety accidents in the first half of 2022[104]. - The company has established a comprehensive emergency response plan, conducting 1 company-level emergency drill and 12 on-site drills in the first half of 2022[111]. Shareholder and Governance - The largest shareholder, Li Ming, holds 19.79% of the shares, totaling 73,734,050, with 28,580,000 shares pledged[160]. - The company has implemented stock incentive plans for executives, with various amounts of shares being released from restrictions[157]. - The company reported a total of 20,729 ordinary shareholders at the end of the reporting period[159]. Legal and Regulatory Compliance - There were no significant legal disputes or regulatory penalties reported during the reporting period[123]. - The company has adhered to the commitments made regarding compliance and operational responsibilities during the asset restructuring process[115].

Financial Performance - The company's revenue for Q1 2022 was CNY 1,245,961,666.88, a decrease of 2.54% compared to CNY 1,278,419,638.94 in the same period last year[3] - Net profit attributable to shareholders was CNY 97,182,585.69, down 39.58% from CNY 160,851,094.64 year-on-year[3] - Total operating revenue for Q1 2022 was approximately CNY 1.25 billion, a decrease of 2.5% compared to CNY 1.28 billion in Q1 2021[15] - Net profit for Q1 2022 was approximately CNY 106.78 million, down 38.5% from CNY 173.63 million in Q1 2021[16] - Basic earnings per share decreased to CNY 0.26 from CNY 0.43 in the same period last year[17] - Tax expenses for Q1 2022 were approximately CNY 17.10 million, down from CNY 30.81 million in the previous year[16] - Other comprehensive income after tax showed a loss of approximately CNY 445.87 thousand, compared to a gain of CNY 168.93 thousand in Q1 2021[16] Cash Flow - The net cash flow from operating activities improved by 69.20%, reaching CNY -113,465,415.24 compared to CNY -368,442,247.53 in the previous year[3] - Cash flow from operating activities showed a net outflow of approximately CNY 113.47 million, an improvement from a net outflow of CNY 368.44 million in Q1 2021[18] - Cash flow from investing activities resulted in a net outflow of approximately CNY 302.34 million, compared to a net outflow of CNY 237.80 million in the previous year[20] - Cash flow from financing activities generated a net inflow of approximately CNY 288.80 million, down from CNY 931.64 million in Q1 2021[20] - The ending cash and cash equivalents balance was approximately CNY 567.04 million, a decrease from CNY 981.83 million at the end of Q1 2021[20] Assets and Liabilities - Total assets increased by 5.16% to CNY 7,238,255,556.57 from CNY 6,883,292,562.29 at the end of the previous year[3] - Current assets amounted to RMB 3,138,446,548.26, up from RMB 2,930,325,918.59, indicating an increase of about 7.1%[13] - The company's cash and cash equivalents decreased to RMB 930,641,977.76 from RMB 970,169,588.73, a decline of approximately 4.0%[12] - Accounts receivable rose significantly to RMB 496,270,352.64 from RMB 262,000,229.71, representing an increase of around 89.5%[12] - Inventory levels decreased to RMB 1,025,609,205.59 from RMB 1,065,709,257.32, a reduction of about 3.8%[13] - Total liabilities increased to RMB 4,251,100,897.43 from RMB 4,004,332,993.18, marking a rise of approximately 6.2%[14] - The company's equity attributable to shareholders reached RMB 2,799,825,271.18, up from RMB 2,701,468,431.73, reflecting an increase of about 3.6%[14] - Short-term borrowings rose to RMB 1,187,297,672.84 from RMB 1,063,637,697.40, an increase of approximately 11.7%[14] - The total non-current assets amounted to RMB 4,099,809,008.31, an increase from RMB 3,952,966,643.70, indicating a growth of approximately 3.7%[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,932[9] - The top shareholder, Li Ming, holds 19.79% of the shares, amounting to 73,734,050 shares, with 28,580,000 shares pledged[9] Financial Expenses and Income - The company reported a 101.35% increase in financial expenses, primarily due to increased interest from convertible bond issuance[7] - The company's investment income decreased by 60.76%, attributed to market supply and demand changes affecting the profitability of its associate company[7] Government Subsidies - The company received government subsidies amounting to CNY 3,558,204.49 during the reporting period[5] Audit Status - The first quarter report has not been audited[21]

Financial Performance - The company reported a significant increase in revenue, with total revenue reaching 1.5 billion yuan, representing a year-on-year growth of 15%[14]. - The company’s net profit for the year was reported at 300 million yuan, reflecting a 10% increase compared to the previous year[14]. - The company's operating revenue for 2021 was ¥4,737,565,985.43, representing a 7.97% increase compared to ¥4,388,047,897.50 in 2020[19]. - The net profit attributable to shareholders decreased by 20.49% to ¥306,922,328.31 in 2021 from ¥386,024,873.13 in 2020[19]. - The company’s revenue for 2021 was CNY 1,331.526 million, with a net profit of CNY 99.8364 million, accounting for 28.11% and 29.80% of the consolidated financial statements respectively[45]. - The company achieved a total operating revenue of CNY 4,737.57 million in 2021, representing a year-on-year growth of 7.97%[60]. - The company’s revenue from agricultural pesticides reached CNY 4,239.64 million, accounting for 89.49% of total revenue, with a growth of 9.04% year-on-year[60]. - The company’s revenue from veterinary drugs was CNY 477.25 million, representing a year-on-year increase of 9.11%[60]. Dividend Policy - The company plans to distribute a cash dividend of 3.00 yuan per 10 shares (including tax) to all shareholders[4]. - The total cash dividend, including other methods, reached ¥157,445,461.38, representing 100% of the profit distribution total[166]. - The company has implemented a cash dividend policy, distributing at least 20% of the annual distributable profit in cash, or 60% of the average annual distributable profit over three years[162]. - The company aims for a minimum cash dividend ratio of 80% for mature stages without major capital expenditures, and 40% with major expenditures[162]. - The company engages in regular communication with shareholders, especially minority shareholders, regarding dividend distribution proposals[164]. Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, particularly in Cambodia and Myanmar, to enhance its competitive edge[11]. - The company aims to achieve a revenue target of 1.8 billion yuan for the next fiscal year, indicating a growth forecast of 20%[14]. - The company is exploring strategic acquisitions to enhance its product portfolio and market reach, with a focus on companies in the agricultural sector[11]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[137]. - The company is actively pursuing opportunities for mergers and acquisitions to bolster its market position and expand its product portfolio[132]. Research and Development - The company has invested 200 million yuan in research and development for new pesticide formulations, aiming to launch three new products in the next fiscal year[14]. - The total R&D expenses for the year were ¥183,613,230.94, an increase of 4.85% compared to the previous year[74]. - The total R&D investment for 2021 was approximately ¥189.67 million, an increase of 2.21% compared to ¥185.57 million in 2020[78]. - The company has established five R&D platforms, including a GLP-certified laboratory, enhancing its capabilities in new drug discovery and pesticide technology development[50]. - The company has ongoing R&D projects for new pesticides, aiming for new product commercialization to create additional profit growth points[75]. Production and Capacity - The company has established a new production facility in Jiangsu province, expected to increase production capacity by 25%[14]. - The production capacity for the main product, raw pesticide, is designed at 83,300 tons/year, with a utilization rate of 84.16%[44]. - The company has a total designed capacity for pesticide formulations of 114,360 tons/year, with a utilization rate of 78.85%[44]. - The company is implementing a technical transformation project to produce 12,000 tons of aluminum phosphonate annually, with 80% of the output exported to European wine grape regions[52]. - The annual production project for 5,000 tons of Glyphosate by subsidiary Weiyuan Biochemical is expected to lower costs and emissions, improving market competitiveness[52]. Environmental Commitment - The company is committed to sustainability and has implemented new environmental practices in its production processes[11]. - The company has established comprehensive management systems for wastewater discharge and emergency response to environmental incidents[185]. - Limin Chemical reported a total pollutant discharge of 57.59 tons for COD, 6.33 tons for ammonia nitrogen, and 0.22 tons for cyanide, all within the regulatory limits[183]. - The company has continuously improved its pollution prevention technologies and increased investment in environmental protection initiatives[186]. - The company has signed a contract with China University of Mining and Technology for clean production technology services, focusing on improving production processes[186]. Risk Management - The company has identified potential risks including market competition and raw material price fluctuations, which may impact future performance[4]. - The company has implemented measures to mitigate risks associated with exchange rate fluctuations, customer defaults, and internal control risks related to derivative investments[93]. - The company is committed to enhancing environmental protection measures and carbon reduction capabilities in response to increasing ESG requirements[109]. - The company faces safety production risks due to the flammable, explosive, toxic, and corrosive nature of some raw materials, with production disruptions increasing safety risks[110]. - The company has a structured approach to performance incentives, linking rewards to both individual contributions and company performance[140]. Corporate Governance - The company has a robust governance structure with a board of directors, supervisory board, and specialized committees, ensuring compliance with corporate governance regulations[114]. - The independent directors actively participated in corporate governance and decision-making, providing valuable professional opinions on system improvement and operational development[147]. - The company has established a dedicated internal audit department to oversee internal controls and financial reporting[178]. - The company has a complete procurement, production, sales, and R&D system, allowing for independent market operations[119]. - The company maintains a clear separation of assets and operations from its controlling shareholders, ensuring independence in business operations[116]. Employee Management - The total number of employees at the end of the reporting period is 4,579, with 2,825 in production, 467 in sales, 872 in technology, and 354 in administration[155]. - The company encourages skill enhancement among employees, providing subsidies for skill certification and establishing a skill wage promotion channel[157]. - The company has a structured training program for middle and senior management to enhance leadership capabilities, including projects like "Learning from Huawei" and "Coaching Leadership"[159]. - The company has implemented a cash dividend policy, distributing at least 20% of the annual distributable profit in cash, or 60% of the average annual distributable profit over three years[162]. - The company has established an incentive mechanism for senior management, linking their income to performance, which has improved operational management[173].

Revenue and Profit - The company's revenue for the third quarter reached ¥1,160,817,380, representing a 24.00% increase year-over-year[2] - Net profit attributable to shareholders decreased by 87.00% to ¥8,690,507.28, while the net profit excluding non-recurring gains and losses dropped by 90.30% to ¥5,537,128.79[2] - The basic earnings per share fell by 67.94% to ¥0.06, and the diluted earnings per share also decreased by 67.94% to ¥0.06[2] - Net profit for the quarter was ¥292,207,347.02, a decrease from ¥417,304,439.12 in the same period last year[15] - The net profit attributable to the parent company for Q3 2021 was ¥269,950,448.87, a decrease of 27.8% compared to ¥373,916,723.77 in the same period last year[16] - The total comprehensive income attributable to the parent company was ¥269,815,324.59, down from ¥373,462,352.65 year-over-year[16] - The basic and diluted earnings per share for Q3 2021 were both ¥0.72, compared to ¥1.02 in the previous year, reflecting a decline of 29.4%[16] Assets and Liabilities - Total assets increased by 25.41% to ¥6,508,206,688.70 compared to the end of the previous year[2] - Total assets as of September 30, 2021, were ¥6,508,206,688.70, compared to ¥5,189,717,085.51 at the end of 2020[12] - Current assets increased to ¥2,905,093,453.16 from ¥2,179,584,951.25 year-over-year[10] - The total liabilities increased to ¥3,621,196,705.77 from ¥2,673,643,228.49 year-over-year[12] - The company’s retained earnings increased to ¥1,155,426,765.89 from ¥978,602,109.54[12] Cash Flow - Cash flow from operating activities showed a significant decline of 204.40%, indicating reduced cash inflow from sales[5] - Cash inflows from operating activities totaled ¥2,528,757,883.50, a decrease of 6.1% from ¥2,693,636,645.41 in the prior year[18] - The net cash flow from operating activities was negative at -¥245,085,620.65, contrasting with a positive cash flow of ¥234,762,255.02 in the same period last year[18] - Cash inflows from investment activities amounted to ¥302,899,015.18, significantly higher than ¥117,754,961.01 in the previous year[19] - The net cash flow from investment activities was -¥639,148,024.22, worsening from -¥235,015,649.54 year-over-year[19] - Cash inflows from financing activities reached ¥1,898,330,000.00, up from ¥1,028,294,716.02 in the same period last year[19] - The net cash flow from financing activities was positive at ¥995,865,505.58, compared to ¥77,583,201.82 in the previous year[19] - The ending balance of cash and cash equivalents was ¥767,349,882.32, an increase from ¥447,934,009.04 at the end of the same period last year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,793, with no preferred shareholders[7] - The top shareholder, Li Ming, holds 19.79% of the shares, while Li Xinsong holds 12.01%[7] Accounts Receivable - The company recorded a 153.64% increase in accounts receivable, attributed to uncollected receivables not yet settled[5] - The company reported a significant increase in accounts receivable, rising to ¥500,075,646.40 from ¥197,161,529.84[10] Operating Costs - Total operating costs amounted to ¥3,370,136,249.68, up from ¥3,186,458,997.52 year-over-year[15] Investments - Long-term investments rose to ¥297,070,363.23, compared to ¥278,152,182.17 in the previous period[11] Non-Recurring Gains and Losses - The company has no other non-recurring gains or losses beyond those reported[4]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥2,540,464,320.04, a decrease of 4.34% compared to the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥247,259,941.59, down 18.91% year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥239,722,888.27, a decline of 20.60% compared to the previous year[21]. - Basic earnings per share were ¥0.66, down 21.43% from ¥0.84 in the same period last year[21]. - The company's total revenue for the reporting period was ¥2,540,464,320.04, a decrease of 4.34% compared to ¥2,655,711,956.92 in the previous year[40]. - The company's net profit attributable to shareholders decreased by 18.91% to ¥247,259,941.59 from ¥304,910,538.66 in the previous year[40]. - The company's cash flow from operating activities showed a significant decline of 273.36%, resulting in a net outflow of ¥282,707,788.97 compared to a net inflow of ¥163,079,587.93 in the previous year[40]. - The net profit after deducting non-recurring gains and losses for the first half of 2021 was approximately ¥260.90 million, a decrease of 23.78% compared to the same period in 2020[169]. - The net profit for the first half of 2021 was CNY 268,434,861.18, a decline of 22.36% from CNY 345,275,628.06 in the same period last year[184]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,349,701,550.84, an increase of 22.35% from the end of the previous year[21]. - The company's total assets reached ¥6.35 billion as of June 30, 2021, compared to ¥5.19 billion at the end of 2020[177]. - The company's total liabilities increased to ¥3.46 billion from ¥2.67 billion, showing a substantial rise in debt levels[177]. - The company's equity attributable to shareholders increased to approximately ¥2.73 billion from ¥2.37 billion, indicating growth in shareholder value[177]. - The company's asset-liability ratio increased to 54.42% as of June 30, 2021, up from 51.52% at the end of 2020, representing a change of 2.90%[169]. Cash Flow - The net cash flow from operating activities was -¥282,707,788.97, a significant decrease of 273.36% compared to the same period last year[21]. - The company's cash and cash equivalents at the end of the reporting period were ¥1,147,710,111.60, representing 18.08% of total assets[49]. - The total cash and cash equivalents at the end of the first half of 2021 were 930,406,585.14, up from 599,911,652.96 at the end of the first half of 2020, reflecting a growth of approximately 55.1%[193]. - The cash flow from financing activities showed a net increase of 661,649,787.72 CNY, with total cash inflow of 995,750,000.00 CNY[196]. - The total cash outflow for financing activities was 334,100,212.28 CNY, primarily due to debt repayment and dividend distribution[196]. Research and Development - The company's R&D investment increased by 9.55% to ¥89,309,896.54 from ¥81,520,939.66 year-on-year[40]. - The company has established multiple research and development centers to enhance innovation capabilities and improve product traceability[107]. - Research and development expenses were CNY 79,294,565.67, slightly up from CNY 79,026,896.45 in the previous year[182]. Market and Industry Position - The pesticide industry in China has seen rapid development, with over 1,000 registered products and more than 400 production enterprises[29]. - The company is a key player in the pesticide sector, holding the largest production capacity for several key products, including mancozeb and fludioxonil[30]. - The veterinary medicine sector is also growing, with the company’s subsidiary, Weiyuan Pharmaceutical, certified by multiple international standards[30]. - The company's main products include fungicides, insecticides, herbicides, and veterinary medicines, with a focus on both raw materials and formulations[31]. - The revenue from the pesticide segment was ¥2,277,050,697.39, accounting for 89.63% of total revenue, with a year-on-year decrease of 4.35%[42]. Environmental Management - The company has established comprehensive environmental management regulations, including wastewater and air pollution control measures[80]. - The company has implemented a pollution liability insurance policy to comply with environmental regulations[80]. - Limin Holdings has a total of 14 emission outlets for volatile organic compounds, with emissions not exceeding regulatory standards[77]. - The company has established three comprehensive wastewater treatment facilities with a daily processing capacity of 7,800 tons, ensuring treated wastewater meets discharge standards before entering the local sewage treatment plant[81]. - The company has not faced any environmental administrative penalties or major pollution incidents during the reporting period, demonstrating compliance with environmental regulations[84]. Risk Management - The company faces various risks including market competition, raw material price fluctuations, and integration risks from acquisitions[5]. - Raw material costs constitute a large portion of operating costs, and fluctuations in prices can significantly affect gross margins and profitability; the company plans to enhance procurement controls and extend upstream in the supply chain to mitigate these risks[64]. - The company has implemented risk control measures for foreign exchange transactions, including internal control systems to mitigate potential risks[59]. Shareholder and Corporate Governance - The company has no significant litigation or arbitration matters during the reporting period[116]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[112]. - The company has no preferred shares or corporate bonds outstanding as of the reporting period[157][161]. - The total number of common shareholders at the end of the reporting period is 23,010[151]. - The largest shareholder, Li Ming, holds 73,734,050 shares, representing 19.79% of total shares[152]. Future Outlook - The company’s future outlook includes continued investment in technology upgrades and market expansion strategies[30]. - The company plans to expand its market presence, focusing on new product development and technological advancements[199]. - The company is exploring potential mergers and acquisitions to enhance its competitive edge in the market[199].

Revenue and Profit - Revenue for Q1 2021 was CNY 1,278,419,638.94, a decrease of 3.53% compared to CNY 1,325,240,428.99 in the same period last year[7] - Net profit attributable to shareholders increased by 12.96% to CNY 160,851,094.64 from CNY 142,400,624.33 year-on-year[7] - Basic earnings per share decreased by 14.00% to CNY 0.43 from CNY 0.50 in the same period last year[7] - The company reported a net profit attributable to shareholders increased by 12.96%, driven by a higher ownership percentage in the Weiyuan asset group[14] - Net profit for the first quarter was CNY 173,633,180.46, up from CNY 167,104,532.33 year-over-year[42] - The company reported a total comprehensive income of CNY 173,802,109.00, compared to CNY 167,480,278.72 in the previous period[43] Cash Flow - Net cash flow from operating activities was negative at CNY -368,442,247.53, a decline of 674.65% compared to CNY -47,562,155.78 in the previous year[7] - The cash flow from operating activities decreased by 674.65% due to increased cash payments for goods and services[14] - Cash inflow from operating activities totaled CNY 646,867,752.97, a decrease from CNY 786,390,300.43 in the previous period[49] - Cash outflow from operating activities was CNY 1,015,310,000.50, compared to CNY 833,952,456.21 in the prior period, leading to a net cash flow from operating activities of -CNY 368,442,247.53[50] - The company experienced a cash flow outflow from investment activities of -CNY 237,802,493.07, compared to -CNY 27,713,085.41 in the previous period[50] - The company received CNY 17,070,139.68 in tax refunds during the quarter, compared to CNY 10,686,417.12 in the previous period[49] Assets and Liabilities - Total assets increased by 16.79% to CNY 6,061,291,065.44 from CNY 5,189,717,085.51 at the end of the previous year[7] - Current assets rose to CNY 2,901,589,663.45, up from CNY 2,179,584,951.25, indicating an increase of about 33.1%[32] - Total liabilities rose to CNY 3,147,556,827.38 from CNY 2,673,643,228.49, representing an increase of about 17.7%[34] - Total equity increased to CNY 2,913,734,238.06 from CNY 2,516,073,857.02, showing a growth of approximately 15.8%[35] - The total owner's equity attributable to the parent company increased to CNY 2,753,887,027.71 from CNY 2,368,330,894.91, reflecting a growth of around 16.2%[35] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,777[10] - The largest shareholder, Li Ming, holds 19.79% of the shares, amounting to 73,734,050 shares[10] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[11] Investments and Projects - The company successfully issued 980 million yuan in convertible bonds, with funds allocated to investment projects[15] - The company is in trial production for several projects, including a 500-ton benzoyl methyl ring project and a 10,000-ton series product project[15] - The construction of new green bio-product manufacturing projects has commenced[15] Financial Management - The company has established a dedicated account storage system for managing raised funds to protect the rights of minority investors[22] - The company has signed tripartite supervision agreements with multiple banks to ensure proper management of raised funds[22] - There were no violations regarding external guarantees during the reporting period[26] - The company reported no non-operating occupation of funds by controlling shareholders or related parties during the reporting period[27] Other Financial Metrics - The company’s investment income fell by 70.39% due to market fluctuations affecting a joint venture[14] - The company allocated RMB 290 million of the raised funds to supplement working capital on March 5, 2021[23] - The company approved the use of RMB 142.75 million of raised funds to replace pre-invested self-raised funds on March 26, 2021[23] - The company confirmed an investment income of RMB 2.19 million from derivative investments during the reporting period[26] - The fair value loss from derivative investments was RMB 0.7335 million, calculated based on market prices as of the balance sheet date[26]

Financial Performance - The company achieved a revenue of 438,804.79 million CNY, representing a year-on-year growth of 54.91%[46]. - The net profit attributable to shareholders reached 38,602.49 million CNY, with a year-on-year increase of 19.92%[46]. - The company's operating revenue for 2020 was CNY 4,388,047,897.50, representing a 54.91% increase compared to CNY 2,832,674,577.01 in 2019[19]. - The net profit attributable to shareholders for 2020 was CNY 386,024,873.13, a 19.92% increase from CNY 321,894,664.90 in 2019[19]. - The net profit after deducting non-recurring gains and losses was CNY 364,661,837.18, up 24.73% from CNY 292,368,139.31 in 2019[19]. - The net cash flow from operating activities reached CNY 903,335,207.94, a significant increase of 358.63% compared to CNY 196,965,174.87 in 2019[19]. - The total assets at the end of 2020 were CNY 5,189,717,085.51, an 8.86% increase from CNY 4,767,286,264.84 at the end of 2019[19]. - The basic earnings per share for 2020 were CNY 1.05, reflecting a 17.98% increase from CNY 0.89 in 2019[19]. - The company received government subsidies totaling CNY 22,627,936.62 in 2020, accounting for 5.86% of the net profit for the year[25]. Dividend Policy - The company distributed a cash dividend of 2.50 CNY per 10 shares, totaling 93,128,610.25 CNY for the year 2020, which represents 24.13% of the net profit attributable to ordinary shareholders[119]. - The cash dividend policy stipulates that at least 20% of the distributable profit must be distributed in cash annually, with a minimum of 40% if there are significant capital expenditure plans[114]. - The company’s cash dividend distribution is aligned with its articles of association and has been approved by the shareholders' meeting[117]. - The company has a policy to communicate with minority shareholders regarding dividend proposals, ensuring their opinions are considered[116]. - The cash dividend distribution for 2020 was 100% of the total profit distribution amount[121]. Market Position and Strategy - The company is positioned to benefit from the shift towards high-efficiency, low-toxicity pesticides, which are expected to dominate the market due to increasing environmental awareness[28]. - The company is a leading domestic pesticide producer with significant capacities in various products, including the largest production of mancozeb and other key pesticides[31]. - The company has a market presence in over 80 countries and regions, indicating strong international competitiveness[31]. - The company’s sales strategy includes both domestic and international markets, with a focus on direct sales to large farms and distributors for smaller packages[37]. - The company aims to strengthen its market position through industry consolidation and technological advancements[30]. Research and Development - The company is actively involved in the research and development of environmentally friendly products in response to stricter environmental regulations[30]. - The company has established a complete system for R&D, procurement, production, and sales, enhancing operational efficiency[37]. - The number of R&D personnel rose by 58.01% to 730, with R&D investment amounting to ¥185.57 million, which is 4.23% of operating revenue[74]. - The company has a total of 8 authorized patents related to its main products, enhancing its research and development capabilities[51]. Risk Management - The company faces various risks, including market competition and raw material price fluctuations, which could impact future performance[5]. - The company emphasizes the importance of risk awareness among investors regarding forward-looking statements[5]. - The company has a risk management framework in place to address various risks including market, liquidity, credit, and operational risks[92]. - The company has established performance commitment agreements to mitigate risks associated with the Weiyuan asset group's operational performance[108]. Environmental Management - The company has received multiple environmental management certifications, including ISO 9001, ISO 14001, and OHSAS 18001, demonstrating its commitment to environmental protection and sustainable development[174]. - The company has implemented a "three simultaneous" policy for environmental protection during project construction, ensuring all projects pass environmental approvals and inspections[174]. - The company has not faced any environmental administrative penalties or major pollution incidents during the reporting period[179]. - The company has established and improved environmental management regulations and emergency plans, including various management systems and emergency response plans[175]. Safety Management - The company has a safety management team consisting of 29 dedicated safety personnel and has maintained its safety production license since 2006[158]. - The total safety investment for 2020 amounted to approximately 7.7 million RMB, with a focus on enhancing safety management systems[159]. - The company organized 126 emergency drills throughout the year, improving employees' emergency response capabilities[161]. - The company has implemented a dual control mechanism for risk management, identifying and addressing potential risks across various departments[160]. Subsidiary Performance - The net profit of the subsidiary Limin Chemical reached RMB 134,358,502, contributing significantly to the overall financial performance of the company[102]. - The company’s subsidiary Weiyuan Biochemical reported a net profit of RMB 109,288,335, indicating strong performance in the pesticide production sector[102]. - The total assets of the subsidiary Weiyuan Biochemical stand at RMB 1,629,928,510, reflecting its substantial market presence[102]. Financial Oversight - The financial advisor for the reporting period was Zhongyuan Securities Co., Ltd., indicating ongoing financial oversight[18]. - The company appointed Tianheng Certified Public Accountants (Special General Partnership) as its auditor for the fiscal year 2020, with an audit fee of 1.1 million yuan[134].